Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ECMO ABI Detection With Hyperfine

NCT: NCT06469801 · RECRUITING

NCT IDNCT06469801
StatusRECRUITING
Start Date2024-07-23
Completion2027-12-01
SponsorChildren's Mercy Hospital Kansas City (OTHER)
First posted
Last updated

Brief Summary

The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.

Frequently Asked Questions

What is ECMO ABI Detection With Hyperfine?

ECMO ABI Detection With Hyperfine is a clinical trial registered under NCT06469801. Current status: RECRUITING.

What is the status of NCT06469801?

The current status of NCT06469801 (ECMO ABI Detection With Hyperfine) is: RECRUITING.

When did ECMO ABI Detection With Hyperfine start?

ECMO ABI Detection With Hyperfine started on 2024-07-23.

Related Devices

K223168Tubing and Accessories Sets for Extracorporeal Membrane Oxygenation (ECMO) with Balance™ BiosurfaceMedtronic, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑